Employees: 03 (2023.0)Legal category: 5485Size: PMECreation date: 1991-01-01 (35 years)Status: ActiveBusiness sector: Commerce de détail de produits pharmaceutiques en magasin spécialiséLocation: SAINT-HIPPOLYTE-DU-FORT (30170), Gard
Les données financières de cette entreprise sont partiellement disponibles (liasse simplifiée ou données confidentielles). Certaines sections ne sont pas affichées.
PHARMACIGALES : revenue, balance sheet and financial ratios
PHARMACIGALES is a French company
founded 35 years ago,
specialized in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé.
Based in SAINT-HIPPOLYTE-DU-FORT (30170),
this company of category PME
shows in 2024 a net income positive of 24 k€.
Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.
Financial history - PHARMACIGALES (SIREN 380983965)
Indicator
2024
2023
2022
2019
Revenue
N/C
N/C
N/C
N/C
Net income
23 954 €
13 486 €
74 611 €
70 420 €
EBITDA
N/C
N/C
N/C
N/C
Net margin
N/C
N/C
N/C
N/C
Revenue and income statement
In 2024, PHARMACIGALES generates positive net income of 24 k€. Net income represents the final profit after all expenses (operating, financial, exceptional) and corporate tax. Change over 2019-2024: 70 k€ -> 24 k€.
Net income (2024)
?
Net income
Definition
Profit or loss after all expenses, including taxes and exceptional items.
Formula
Current income + Exceptional income - Income tax
23 954 €
Loading income statement...
Income statement
Item
Amount
% Revenue
Change
The detailed income statement is not available for this company (simplified accounts or confidential data).
Chart evolution
Show :
Visualization created via numbers.finance Sources : INPI & BCE - Adjustments : Ministry of Economy
Assets
Loading data...
Item
Gross
Deprec.
Net
%
Change
Assets balance sheet data not available for this company
Liabilities
Loading data...
Item
Year
%
Change
Liabilities balance sheet data not available for this company
Solvency and debt ratios
The debt ratio (= Financial debt / Equity x 100) stands at 57%. Debt remains under control: the company retains capacity to raise new debt if needed. Financial autonomy (= Equity / Total assets x 100) reaches 52%. This high autonomy means the company finances most of its assets through equity, a sign of strength.
Debt ratio (2024)
?
Debt ratio
Definition
Measures the proportion of debt to equity.
Formula
(Financial debt / Equity) x 100
Interpretation
< 50% : Low 50-100% : Moderate > 100% : High
56.838%
Financial autonomy (2024)
?
Financial autonomy
Definition
Share of equity in the company's total financing.
Formula
(Equity / Total assets) x 100
Interpretation
> 30% : Good autonomy 20-30% : Average < 20% : Low
51.692%
Asset age ratio (2024)
?
Asset age ratio
Definition
Measures the degree of wear of tangible assets.
Formula
Accumulated depreciation / Gross fixed assets x 100
Visualization created via numbers.finance Sources : INPI & BCE - Adjustments : Ministry of Economy
Indicator
2019
2022
2023
2024
Debt ratio
383.783
98.262
76.81
56.838
Financial autonomy
16.287
43.004
46.699
51.692
Repayment capacity
None
None
None
None
Cash flow / Revenue
None%
None%
None%
None%
Sector positioning
Debt ratio
56.842024
2022
2023
2024
Q1: 16.46
Med: 58.48
Q3: 154.77
Good-6 pts over 3 years
In 2024, the debt ratio of PHARMACIGALES (56.84) ranks below the median of the sector. This ratio measures the weight of debt relative to equity. This controlled position reflects prudent management.
Financial autonomy
51.69%2024
2022
2023
2024
Q1: 28.91%
Med: 49.95%
Q3: 69.47%
Good+8 pts over 3 years
In 2024, the financial autonomy of PHARMACIGALES (51.7%) ranks above the median of the sector. This ratio represents the share of equity in total financing. This comfortable position offers an appreciable safety margin.
Liquidity ratios
The liquidity ratio (= Current assets / Current liabilities) stands at 144.70. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months.
Liquidity ratio (2024)
?
Liquidity ratio
Definition
Ability to meet short-term debts with current assets.
Formula
Current assets / Current liabilities
Interpretation
> 1.5 : Very good 1-1.5 : Fair < 1 : Liquidity risk
144.699
Liquidity indicators evolution PHARMACIGALES
Visualisation créée via abddaf.fr Sources : INPI & BCE - Retraitements : Ministère de l'économie
Indicator
2019
2022
2023
2024
Liquidity ratio
116.853
216.748
170.465
144.699
Interest coverage
None
None
None
None
Sector positioning
Liquidity ratio
144.72024
2022
2023
2024
Q1: 129.46
Med: 182.14
Q3: 260.79
Average-24 pts over 3 years
In 2024, the liquidity ratio of PHARMACIGALES (144.70) ranks below the median of the sector. This ratio measures the ability to cover short-term debt with current assets. An improvement would strengthen the competitive position.
Positioning of PHARMACIGALES in its sector
Comparison with sector Commerce de détail de produits pharmaceutiques en magasin spécialisé
Valuation estimate
Based on 225 transactions of similar company sales
in 2024,
the value of PHARMACIGALES is estimated at
334 415 €
(range 232 881€ - 500 304€).
This multiples method compares the actual sale price of similar companies to their financial indicators (Revenue, EBITDA, Net Income). It provides a market-based indicative estimate.
Estimated enterprise value2024
225 transactions
232k€334k€500k€
334 415 €Range: 232 881€ - 500 304€
NAF 5 année 2024
Valuation method used
Net Income Multiple
23 954 €
×
14.0x
=334 416 €
Range: 232 882€ - 500 305€
Only this financial indicator is available for this company.
Valuation evolution
Visualisation creee via abddaf.fr Sources : BODACC & INPI
How is this estimate calculated?
This estimate is based on the analysis of 225 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.
EBITDA Multiple: Preferred method for profitable SMEs. EBITDA reflects the ability to generate cash.
Revenue Multiple: Used for growing companies or those with low profitability. Reflects commercial potential.
Net Income Multiple: Relevant for mature companies with stable results.
This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).
Similar companies (Commerce de détail de produits pharmaceutiques en magasin spécialisé)
Compare PHARMACIGALES with other companies in the same sector:
The revenue of PHARMACIGALES is not publicly disclosed (confidential accounts filed with INPI).
Is PHARMACIGALES profitable?
Yes, PHARMACIGALES generated a net profit of 24 k€ in 2024.
Where is the headquarters of PHARMACIGALES ?
The headquarters of PHARMACIGALES is located in SAINT-HIPPOLYTE-DU-FORT (30170), in the department Gard.
Where to find the tax return of PHARMACIGALES ?
The tax return of PHARMACIGALES is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).
In which sector does PHARMACIGALES operate?
PHARMACIGALES operates in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé (NAF code 47.73Z). See the 'Sector positioning' section above to compare the company with its competitors.
Item evolution
Rotate your phone to landscape mode to view the chart